AAP
MLYS icon

Arax Advisory Partners’s Mineralys Therapeutics MLYS Stock Holding History

Arax Advisory Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.87K Sell
69
-40
-37% -$1.17K ﹤0.01% 3126
2025
Q4 		$3.96K Sell
109
-161
-60% -$6.46K ﹤0.01% 2974
2025
Q3 		$10.2K Buy
+270
New +$5.84K ﹤0.01% 2585
2025
Q1 		– Sell
-108
Closed -$1.33K – 2901
2024
Q4 		$1.33K Hold
108
– – ﹤0.01% 2105
2024
Q3 		$1.31K Hold
108
– – ﹤0.01% 2178
2024
Q2 		$1.26K Buy
+108
New +$1.36K ﹤0.01% 2104

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Arax Advisory Partners's MLYS Position: Q1 2026 in Review

Arax Advisory Partners reduced its Mineralys Therapeutics (MLYS) stake by 37% in Q1 2026, selling an estimated $1.17K and leaving 69 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #3126.

Arax Advisory Partners first reported a position in MLYS in Q2 2024 and has held it in 6 quarters since. The position peaked at $10.2K in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Arax Advisory Partners held 69 shares of Mineralys Therapeutics worth $1.87K as of Q1 2026.
  • Arax Advisory Partners sold 40 Mineralys Therapeutics shares in Q1 2026, an estimated $1.17K.
  • Mineralys Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3126 holding.
  • Arax Advisory Partners first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Mineralys Therapeutics position peaked at $10.2K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.